Compare Davita Inc (DVA) vs 3M Company (MMM) Price & Performance

DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.

Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.

3M (MMM) trades at $159.96, down 1.33% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.40 versus $2.25 expected, and maintains a robust net income margin of 11.9%. Recent news highlights operational momentum, including raised guidance and progress on litigation management. Cash flow from operations improved to $2.31 billion in 2025, though net cash flow was negative $319 million due to financing activities.

The outlook is mixed; analyst consensus is a Buy with a $191 price target, implying 19% upside, but technical indicators suggest near-term pressure. Key risks include high debt levels, weak consumer segment demand, and cost pressures. Earnings growth and margin expansion remain critical for sustained stock appreciation amid competitive and macroeconomic challenges.